Product Information
EDARBYCLOR 40-25 MG TABLET is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $8.4902 per EA under NDC 60631042530. Its NADAC has been published 606 times since Feb 25, 2015.
FDA first approved this application on Dec 20, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40; 25 mg/1; mg/1
Manufacturer
Azurity Pharmaceuticals Inc.NDC
60631042530
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONEApproval Type
New Drug (NDA)
FDA Application
NDA202331FDA Approved
12/20/2011
TE Code
AB
On Market Since
2/1/2013
Pharmacological Classes
Price Statistics
The NADAC for EDARBYCLOR 40-25 MG TABLET has been published 606 times since Feb 25, 2015, and over the history we have for it it has risen 88.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.4902 per EA |
|---|---|
| All-time high | $8.5037 (May 14, 2025) |
| All-time low | $4.5107 (Feb 25, 2015) |
| 52-week high | $8.4978 |
| 52-week low | $8.4618 |
| Median price | $6.4445 |
| Average price | $6.6034 |
| Largest weekly change | +10.0% (Dec 27, 2023) |
| Weeks tracked | 606 |
| Tracking since | Feb 25, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Azilsartan kamedoxomil and chlorthalidone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Azilsartan kamedoxomil and chlorthalidone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EDARBYCLOR 40-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EDARBYCLOR 40-25 MG TABLET, manufactured by Azurity Pharmaceuticals Inc., is $8.4902 per EA (NDC 60631042530), effective Sep 30, 2026.
How has the price of EDARBYCLOR 40-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for EDARBYCLOR 40-25 MG TABLET has risen 88.2%. It has been tracked across 606 weekly CMS publications since Feb 25, 2015.
What are the highest and lowest recorded NADAC prices for EDARBYCLOR 40-25 MG TABLET?
Since Feb 25, 2015, the NADAC for EDARBYCLOR 40-25 MG TABLET has ranged from a low of $4.5107 (Feb 25, 2015) to a high of $8.5037 (May 14, 2025), with a median of $6.4445 per EA.
Are there cheaper alternatives to EDARBYCLOR 40-25 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of EDARBYCLOR 40-25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EDARBYCLOR 40-25 MG TABLET?
EDARBYCLOR 40-25 MG TABLET (NDC 60631042530) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.